1GARCIA DA, BAGLIN TP, WEITZ JI, et al. Parenteralanticoagulants : antithrombotic therapy and prevention ofthrombosis,9th ed: American College of Chest Physiciansevidence-based clinical practice guidelines[J]. Chest, 2012,141(2 Suppl) : e24S-e43S.
2AGENO W, GALLUS AS, WITTKOWSKY A, et al. Oralanticoagulant therapy : antithrombotic therapy and prevention ofthrombosis,9th ed : American College of Chest Physiciansevidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl): e44S-88S.
3NUTESCU E. Apixaban: a novel oral inhibitor of factor Xa[J].Am J Health Syst Pharm, 2012, 69(13) : 1113-1126.
4PERZBORN E, ROEHRIG S,STRAUB A, et al. The discoveryand development of rivaroxaban, an oral, direct factor Xainhibitor[J]. Nat Rev Drug Discov, 2011,10(1): 61-75.
5TUSZYNSKI GP, GASIC TB, GASIC GJ. Isolation andcharacterization of antistasin. An inhibitor of metastasis andcoagulation[J]. J Biol Chem, 1987,262(20): 9718-9723.
6NUTT E,GASIC T, RODKEY J, et al. The amino acidsequence of antistasin. A potent inhibitor of factor Xa reveals arepeated internal structure [J]. J Biol Chem, 1988,263 (21):10162-10167.
7BECKER RC, ALEXANDER J, DYKE CK,et al. Developmentof DX - 9065a, a novel direct factor Xa antagonist, incardiovascular disease[J]. Thromb Haemost, 2004, 92(6) : 1182-1193.
8SATO K, KAWASAKI T,TANIUCHI Y, et al. YM-60828, anovel factor Xa inhibitor: separation of its antithrombotic effectsfrom its prolongation of bleeding time[J]. Eur J Pharmacol,1997,339(2-3): 141-146.
9TANIUCHI Y, SAKAI Y,HISAMICHI N, et al. Biochemicaland pharmacological characterization of YM -60828,a newlysynthesized and orally active inhibitor of human factor Xa [J].Thromb Haemost, 1998,79(3): 543-548.
10MIYARES MA,DAVIS K. Newer oral anticoagulants: a reviewof laboratory monitoring options and reversal agents in thehemorrhagic patientfj]. Am J Health Syst Pharm, 2012,69(17):1473-1484.
2Schoenfeld P. Gastrointestinal safety profile of meloxicam: a metanalysis and systematic review of randomized controlled trials. Am J Med, 1999; 107 (6A) : 48 ～ 54
3Daly AK, Brockmoller J, Broly F. Nomendature for human CYP2D6 alleles. Pharmacogenetics, 1996; 6:193
4Manyike PT, Kharasch ED, Kachorn TF et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther , 2000 ; 67 ( 3 ) : 279～82
5Chesne C,Guguomard C,Guillouzo A et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotia, 1998; 28( 1 ) : 1 ～ 13
6Tang W, Steams RA, Wang RW et al. Roles of human hepatic cytochrome P4502C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol,1999;12(2): 192～9
7Tracy TS, Marra C, Wrighton SA et al. Studies of flurbiprofen 4'-hydroxylation: Additional evidence suggesting the sole involvement of cytochrome P450. Biochem Pharmacol, 1996; 52 (8): 1305 ～ 9
8Miners JO, Couttor S, Tukey RH et al. Cytochrome P450,1A2,and 2C9 are responsible for the human hepatic O-demethylation of R and S-naproxen. Biochem Pharmacol, 1996;51(8): 1003～8
9Miners JO, Birkett DJ. Cytochrome P450 2C9. An Enzyme of Major Importance in human Drug Metabolism. Br J Clin Pharmacol,1998;45(6): 525～38
10Takanashi K, Tainaka H, Kobayashi K et al. CYP2C9 Ile 359 and Leu 359 variants: enzyme kinetic study with seven substrates.Pharmacogenetics ,2000; 10(20): 95 ～ 104
